Skip to main content
. 2021 Feb 1;12(2):139. doi: 10.1038/s41419-021-03431-2

Fig. 4. GSDME-N promoted cisplatin-induced cell injury and pyroptosis in human TECs.

Fig. 4

Human TECs (HK-2) were transfected with GSDME-N (residues 1–270aa) overexpressing plasmid and subsequently treated with cisplatin (10 μg/mL) for 24 h. a Protein levels of HA-GSDME-N in cells by immunoblotting with HA and GSDME antibody. b Transcriptional levels of KIM-1 (n = 3). c Representative bright-field microscopic images of cells treated with cisplatin in the presence or absence of GSDME-N. Red arrowheads indicate large bubbles from the plasma membrane (scale bar = 50 μm). d LDH release of cells transfected with GSDME-N in the presence of cisplatin treatment (n = 6). e PI staining of cells with GSDME-N overexpression (scale bar = 100 μm; n = 3). f CCK-8 assay was performed to assess the effect of GSDME-N on cell viability (n = 6). g ELISA results of IL-1β and IL-6 in cultured medium of cells with GSDME-N overexpression (n = 3). h The effect of GSDME-N on p-p65 protein levels (n = 3). *P < 0.05, **P < 0.01, and ***P < 0.001.